Fierro J, Velasquez-Berrio M, Ospina A, Henning S, de Leeuw K, Cadavid J A
Rheumatol Int. 2023; 44(2):223-234.
PMID: 37741812
PMC: 10796698.
DOI: 10.1007/s00296-023-05457-5.
Mayer-Pickel K, Nanda M, Gajic M, Cervar-Zivkovic M
Biomedicines. 2023; 11(8).
PMID: 37626793
PMC: 10452741.
DOI: 10.3390/biomedicines11082298.
DIppolito S, Barbaro G, Paciullo C, Tersigni C, Scambia G, Di Simone N
Int J Mol Sci. 2023; 24(4).
PMID: 36834614
PMC: 9966557.
DOI: 10.3390/ijms24043195.
Niznik S, Rapoport M, Avnery O, Lubetsky A, Shavit R, Ellis M
Front Pharmacol. 2022; 13:824775.
PMID: 35529433
PMC: 9068935.
DOI: 10.3389/fphar.2022.824775.
Park J, Lee Y, Park J, Lee E, Song Y
Cells. 2021; 10(5).
PMID: 34068752
PMC: 8151692.
DOI: 10.3390/cells10051151.
Are antiphospholipid antibodies just a common epiphenomenon or are they causative of immune-mediated coagulopathy in COVID-19?.
Castillo-Martinez D, Torres Z, Amezcua-Guerra L, Pineda C
Clin Rheumatol. 2021; 40(7):3015-3019.
PMID: 33826045
PMC: 8024929.
DOI: 10.1007/s10067-021-05724-5.
Antithrombotic therapy to prevent recurrent pregnancy loss in antiphospholipid syndrome-What is the evidence?.
Hamulyak E, Scheres L, Goddijn M, Middeldorp S
J Thromb Haemost. 2021; 19(5):1174-1185.
PMID: 33687789
PMC: 8252114.
DOI: 10.1111/jth.15290.
Changes of lipoxin levels during pregnancy and the monthly-cycle, condition the normal course of pregnancy or pathology.
Szczuko M, Palma J, Kikut J, Komorniak N, Zietek M
Inflamm Res. 2020; 69(9):869-881.
PMID: 32488315
PMC: 7395003.
DOI: 10.1007/s00011-020-01358-6.
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Hamulyak E, Scheres L, Marijnen M, Goddijn M, Middeldorp S
Cochrane Database Syst Rev. 2020; 5:CD012852.
PMID: 32358837
PMC: 7195627.
DOI: 10.1002/14651858.CD012852.pub2.
Obstetric Anti-phospholipid Syndrome: State of the Art.
Gerardi M, Fernandes M, Tincani A, Andreoli L
Curr Rheumatol Rep. 2018; 20(10):59.
PMID: 30105597
DOI: 10.1007/s11926-018-0772-y.
Low molecular weight heparin and aspirin exacerbate human endometrial endothelial cell responses to antiphospholipid antibodies.
Quao Z, Tong M, Bryce E, Guller S, Chamley L, Abrahams V
Am J Reprod Immunol. 2017; 79(1).
PMID: 29135051
PMC: 5728699.
DOI: 10.1111/aji.12785.
Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome-Biomarkers of the Disease and Biopharmaceuticals.
Becarevic M
Curr Rheumatol Rep. 2017; 19(7):40.
PMID: 28631067
DOI: 10.1007/s11926-017-0669-1.
Plasma levels of high-mobility group box 1 and soluble receptor for advanced glycation end products in primary antiphospholipid antibody syndrome patients.
Tang K, Hsieh T, Chao Y, Lin M, Chen Y, Chen D
PLoS One. 2017; 12(5):e0178404.
PMID: 28558055
PMC: 5448773.
DOI: 10.1371/journal.pone.0178404.
TNF-alpha and annexin A2: inflammation in thrombotic primary antiphospholipid syndrome.
Becarevic M
Rheumatol Int. 2016; 36(12):1649-1656.
PMID: 27704162
DOI: 10.1007/s00296-016-3569-1.
Pregnancy Outcome in Women with Obstetric and Thrombotic Antiphospholipid Syndrome-A Retrospective Analysis and a Review of Additional Treatment in Pregnancy.
Mayer-Pickel K, Eberhard K, Lang U, Cervar-Zivkovic M
Clin Rev Allergy Immunol. 2016; 53(1):54-67.
PMID: 27395067
DOI: 10.1007/s12016-016-8569-0.
Antiphospholipid antibody-induced miR-146a-3p drives trophoblast interleukin-8 secretion through activation of Toll-like receptor 8.
Gysler S, Mulla M, Guerra M, Brosens J, Salmon J, Chamley L
Mol Hum Reprod. 2016; 22(7):465-74.
PMID: 27029214
PMC: 4941806.
DOI: 10.1093/molehr/gaw027.
Placental origins of adverse pregnancy outcomes: potential molecular targets: an Executive Workshop Summary of the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Ilekis J, Tsilou E, Fisher S, Abrahams V, Soares M, Cross J
Am J Obstet Gynecol. 2016; 215(1 Suppl):S1-S46.
PMID: 26972897
PMC: 4925329.
DOI: 10.1016/j.ajog.2016.03.001.
The Effects of NF-κB and c-Jun/AP-1 on the Expression of Prothrombotic and Proinflammatory Molecules Induced by Anti-β2GPI in Mouse.
Xia L, Xie H, Yu Y, Zhou H, Wang T, Yan J
PLoS One. 2016; 11(2):e0147958.
PMID: 26829121
PMC: 4735462.
DOI: 10.1371/journal.pone.0147958.
Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE: a retrospective cohort study.
Broder A, Mowrey W, Kim M, Murakhovskaya I, Billett H, Neugarten J
Rheumatology (Oxford). 2015; 55(5):817-25.
PMID: 26705328
PMC: 5009419.
DOI: 10.1093/rheumatology/kev423.
Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers.
Meroni P, Chighizola C, Rovelli F, Gerosa M
Arthritis Res Ther. 2014; 16(2):209.
PMID: 25166960
PMC: 4060447.
DOI: 10.1186/ar4549.